Argenx (ARGX) said Friday that Japan's Ministry of Health, Labour and Welfare approved its Vyvdura injection as a treatment for adult patients with chronic inflammatory demyelinating polyneuropathy, a progressive and debilitating neuromuscular disorder of the peripheral nervous system.
The approval is based on the results of a study, which showed that 69% of patients treated with the drug demonstrated clinical improvements, including in mobility, function and strength.
The Japanese regulator approved Vyvdura for manufacturing and marketing in January. The drug was launched in April for the treatment of generalized myasthenia gravis.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.